Donna has more than 20 years of experience in leading biotech companies and bringing novel products to market. Between 2004 and 2011 Ms. Janson served as President and CEO of Novalar Pharmaceuticals Inc., a specialty pharmaceutical company with a first-in-class local anesthetic reversal agent. Ms. Janson oversaw the clinical development through commercialization of Novalar’s principal product OraVerse. She also led two successful financing rounds and managed the acquisition of OraVerse by Septodont during her tenure. Prior to this, Ms. Janson served as President and CEO of Biora AB, a public biotech company specializing in periodontal regeneration. Ms. Janson managed the acquisition of Biora by Straumann. Prior to being appointed CEO, Ms. Janson served as president of Biora Inc., the North American subsidiary of Biora AB. In this role, she was responsible for establishing Biora, Inc. She currently serves as a board member of The McGuire Institute, a practice based clinical research network.
Carlos Gonzalez joins Nasseo as a Regulatory and Quality consultant to management, with more than 40 years of experience serving vital roles in engineering, operations, regulatory affairs, quality assurance and corporate compliance. Mr. Gonzalez' career spanned operational roles in biologics at Alpha Therapeutics as well as engineering and quality roles in high volume medical device production at Baxter and Stryker. Prior to joining the Nasseo team, Mr. Gonzalez served as vice president of regulatory affairs, quality assurance and corporate compliance for Stryker Endoscopy, a division of Stryker Corp. At Stryker, Carlos was responsible for nearly 100 successful FDA 510(k) submissions and dozens of foreign product submissions over 15 years. His leadership contributed to the growth of three newly acquired business units; taking the company from 55 to over 1000 employees and from $60 million to over $550 million in revenues.
Dr. Smith holds a BS in Biosystems Engineering from the University of Arizona, and a MS and a PhD in Bioengineering from the University of California, San Diego. A published scientist and inventor on over a dozen pending or issued patents, Dr. Smith helped develop Nasseo's proprietary surface modification technology and FDA cleared TiArray™ Dental Implant System. Dr. Smith leads Nasseo's research and development and product development initiatives, drawing upon his experience with medical device startups. Dr. Smith previously worked with NuVasive, Inc. and Moximed, Inc. and co-founded Oculeve, Inc. a medtech start-up which was acquired by Allergan PLC. Garrett completed the Stanford Biodesign Program where he also served as a Biodesign Fellow in 2010-2011.
Gary earned a PhD from the Materials Science Department at the University of California, San Diego focusing on surface modification technologies pertaining to various substrate materials that are utilized in dental and orthopedic implants. Gary has helped develop Nasseo's proprietary surface modification technology, is furthering the research and development of Nasseo’s TiArray™ Dental Implant System, and is furthering the research and development of additional applications for Nasseo's proprietary surface modification technology such as craniofacial plates and interbody fusion devices. Gary is also leading Nasseo’s quality system compliance and manufacturing initiatives. Gary previously worked at NuVasive, Inc. in their Quality Engineering Department.
Nasseo's Board of Directors includes:
Nasseo's Board of Advisors includes:
Nasseo's Board of Clinicians includes: